{"id":"acalabrutinib-combination-with-rituximab","safety":{"commonSideEffects":[{"rate":"44%","effect":"Neutropenia"},{"rate":"34%","effect":"Anemia"},{"rate":"31%","effect":"Thrombocytopenia"},{"rate":"28%","effect":"Diarrhea"},{"rate":"24%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling complex. Inhibition of BTK has been shown to be effective in treating certain types of non-Hodgkin lymphoma.","oneSentence":"BTK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:33.498Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT02717624","phase":"PHASE1","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-04-20","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":72},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":611},{"nctId":"NCT02296918","phase":"PHASE1","title":"Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia","enrollment":69},{"nctId":"NCT03342144","phase":"","title":"Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","status":"RECRUITING","sponsor":"AbbVie","startDate":"2017-12-04","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":500},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT05951959","phase":"PHASE2","title":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":108},{"nctId":"NCT02180711","phase":"PHASE1, PHASE2","title":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-12-29","conditions":"Non Hodgkin Lymphoma","enrollment":113},{"nctId":"NCT04546620","phase":"PHASE2","title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2021-10-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":453},{"nctId":"NCT03863184","phase":"PHASE2","title":"Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-10-11","conditions":"Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT06846489","phase":"PHASE2","title":"Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-14","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":50},{"nctId":"NCT04189952","phase":"PHASE2","title":"Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2020-09-22","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT03571568","phase":"PHASE1, PHASE2","title":"A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL","status":"RECRUITING","sponsor":"BioInvent International AB","startDate":"2018-05-16","conditions":"Indolent B-Cell Non-Hodgkin Lymphoma","enrollment":140},{"nctId":"NCT04666038","phase":"PHASE3","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-03-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":238},{"nctId":"NCT03492125","phase":"PHASE1, PHASE2","title":"A Study Of The Selective PKC-β Inhibitor MS- 553","status":"TERMINATED","sponsor":"MingSight Pharmaceuticals, Inc","startDate":"2018-05-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma","enrollment":60},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT03836261","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2019-02-25","conditions":"Chronic Lymphocytic Leukemia","enrollment":984},{"nctId":"NCT06441097","phase":"PHASE2","title":"Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT06319456","phase":"PHASE3","title":"A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-04-07","conditions":"CLL/SLL","enrollment":344},{"nctId":"NCT05214183","phase":"PHASE2","title":"Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nordic Lymphoma Group","startDate":"2021-12-15","conditions":"MCL, Mantle Cell Lymphoma","enrollment":81},{"nctId":"NCT03571308","phase":"PHASE1, PHASE2","title":"A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2017-06-02","conditions":"Non Hodgkin Lymphoma","enrollment":39},{"nctId":"NCT05820841","phase":"PHASE3","title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-06-07","conditions":"Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":330},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT03527147","phase":"PHASE1","title":"Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2018-06-19","conditions":"NHL, DLBCL, Non-hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT02735876","phase":"PHASE3","title":"A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Acerta Pharma BV","startDate":"2016-05","conditions":"Mantle Cell Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maintenance Phase"],"phase":"phase_2","status":"active","brandName":"Acalabrutinib combination with Rituximab","genericName":"Acalabrutinib combination with Rituximab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}